Aethlon Medical (AEMD) stock rocketed higher on Thursday after the medical technology company made two filings with the Securities and Exchange Commission (SEC). The first filing with the SEC was a request to withdraw an offering statement filed with the organization on December 27, 2024. The company said it decided to withdraw this offering statement due to market conditions. It noted that the offering statement hadn’t been declared qualified by the SEC and that no securities were sold in connection with it.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The withdrawal of the offering statement likely boosted investor confidence. It acts as a positive sign for the company, showing it doesn’t need to sell more shares to raise funds. Investors often appreciate this, as it means their stakes in AEMD stock won’t be diluted by the offering. However, there’s still that second SEC filing to consider.
The second SEC filing concerns an offering that currently lacks details. It doesn’t list how many shares will be offered, or what they will be priced at. What is included in it is the resale of shares from selling stockholders, with 1.55 million shares that may be sold from time to time. As these share sales will be from stockholders, Aethlon Medical would see no proceeds from them, but could receive funds from potential warrant exercises.
Aethlon Medical Stock Movement Today
Aethlon Medical stock was up 61.62% in pre-market trading on Thursday, following a 1.77% dip yesterday. The shares have fallen 83.87% year-to-date and 72.89% over the past 12 months. Today’s news came alongside heavy trading of AEMD stock, with some 30 million units traded, compared to a three-month daily average of about 361,000 units.
Is Aethlon Medical Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Aethlon Medical is Hold, based on two Hold ratings over the past three months. With that comes an average AEMD stock price target of $1.50, representing a potential 35.14% upside for the shares.
